Prior Authorization Workflow: A Safer Queue Design for Community Pharmacies

Prior authorization work becomes unsafe when it is treated as a pile of faxes, portal messages, and verbal promises. A community pharmacy needs a visible queue: one record for each barrier, a named owner, a next action, a deadline, and a clinically sensible escalation path.

Answer first: design prior authorization as an exception-management process, not a technician’s inbox. Capture the coverage question and urgency at intake, separate plan-specific requirements from clinical facts, document every handoff, and close the loop with the patient and prescriber. A good queue will not eliminate payer requirements, but it makes delays, missing information, and stalled handoffs visible soon enough to act.

This article is general operational education, not individualized medical, legal, or payer-contract advice. Coverage rules, prescriber responsibilities, appeal rights, and urgent-review criteria vary by benefit and jurisdiction. Pharmacies should use the applicable plan materials and involve the prescriber, counsel, or reimbursement experts when a case requires them.

Contents

• Why the queue is a patient-safety control
• Build a reliable intake record
• Use lanes instead of one generic worklist
• Escalate with evidence, not urgency theater
• Define ownership and handoffs
• Measure delay without gaming the metric
• Keep Medicare rules in their proper lane
• Implementation checklist
• Frequently asked questions

Key takeaways

• Open one traceable case for each authorization barrier; do not let work live only in a portal or voicemail.
• Record the plan, drug, prescriber, clinical urgency, required document, next action, owner, and deadline at the start.
• Separate routine missing-information cases from therapy-interruption and clinically urgent cases.
• Do not describe every denial as an appeal or every delay as a payer error; first identify the decision and the governing process.
• Use measured turnaround and aging data to improve workflow, not to pressure staff to close unresolved cases.

Why the queue is a patient-safety control

A prior authorization barrier has at least two dimensions: the coverage work and the patient’s medication need. A queue that only lists a rejection message can obscure both. The team needs to know whether the prescription is new or ongoing, whether a dose is due, whether a clinically appropriate alternative is already available, who may submit the required information, and when the patient should hear from the pharmacy again. Those are operating facts, not assumptions about whether the plan will ultimately approve coverage.

The operational failure is often not a single rejection. It is an unowned handoff: a request sent to a prescriber without a documented recipient, a portal response never reconciled to the pharmacy system, a renewal request identified only after the last fill, or a patient told to “check back” without a date. Build the queue to expose those conditions. A case should remain open until the pharmacy has recorded a disposition and the next person who needs to know has been informed.

Start with a short definition. For this workflow, a prior-authorization case is any prescription for which coverage cannot proceed until a plan, prescriber, or other authorized party completes a stated utilization-management step. That definition intentionally includes a request for more information and a renewal that is approaching expiration. It does not convert every rejected claim into prior authorization; refill-too-soon, eligibility, inventory, and coordination-of-benefits issues need their own routes.

Build a reliable intake record

The first person who recognizes the barrier should create the case. Require enough fields to make the next action possible, but not so many that staff create side notes instead. Use the payer response and plan materials as the source for coverage requirements; do not rely on a patient’s recollection of a call or on a generic script.

At intake, ask one operational question before asking five more: what can the pharmacy do today? The answer may be to request information from the prescriber, confirm the plan’s stated process, discuss a lawful cash-price option if the patient asks, or arrange a pharmacist conversation about the need for a prescriber-directed alternative. It is not to promise approval, advise a patient to stop therapy, or substitute a medication without authorization.

Make the next action explicit

“PA sent” is not a useful disposition. It does not tell the next employee whether the plan received a request, whether the prescriber’s office has the needed clinical information, or when follow-up is due. Replace it with a concrete action: “Faxed plan-requested form to prescriber nurse line at 10:15; confirmation retained; follow up at 2:00 tomorrow,” or “Plan portal requests chart note dated within stated period; prescriber office notified through documented channel.” Specific language makes the case auditable and reduces duplicate outreach.

Use lanes instead of one generic worklist

A single list encourages the team to work whatever is newest or loudest. A safer design sorts cases by the kind of decision and the risk of delay. The categories should be local and simple enough to use consistently. They are workflow labels, not clinical triage diagnoses.

Lane 1: information or administrative correction

These cases have a defined missing item, an incorrect identifier, or a plan instruction that can be verified. Assign them a short next-review interval and a standardized evidence checklist. The aim is to resolve a fixable administrative problem quickly while retaining proof of what the plan requested and what was sent.

Lane 2: prescriber-dependent authorization

Some requests depend on clinical rationale, chart information, or a prescriber’s decision. The pharmacy can coordinate, explain the plan’s stated request, and keep the patient informed, but it should not manufacture clinical justification. Record the receiving office, recipient, request date, and scheduled follow-up. Escalate internally when an expected therapy start or continuation is at risk; the escalation should call for a pharmacist or prescriber-team decision, not a fictional promise to the patient.

Lane 3: potential therapy interruption or urgent concern

This lane deserves immediate pharmacist visibility. Define the trigger with your pharmacist-in-charge and clinical policies: for example, an imminent refill gap, a medication the patient reports taking now, or a patient who reports a change in condition. The pharmacist can assess the appropriate communication and escalation route. Front-end staff should not independently determine medical urgency, but they should be trained to recognize the flags and bring the record forward promptly.

Lane 4: decision, denial, or appeal-path review

Do not assume that a rejection message is a final coverage determination. Identify the plan, the stated decision, the notice or portal information, and the applicable process before using words such as appeal, exception, or grievance. A pharmacy can help a patient and prescriber organize the record, but the plan’s rules determine who may request which review and by when. Preserve the source notice and the date it was received.

Escalate with evidence, not urgency theater

A useful escalation packet is modest: the prescription facts, plan message, requested information, what has already been sent, the case timeline, and the specific question that needs a decision. If the prescriber’s office needs to act, say exactly what the plan appears to request and attach the plan’s form or link where available. If the patient needs an update, explain the current step, what the pharmacy is waiting for, and when the next update will occur. Avoid predicting coverage or criticizing a plan when the facts are not established.

When a case involves a patient-safety concern, route it to a pharmacist according to the pharmacy’s policy. That step is distinct from the payer process. The pharmacist may determine that prompt communication with the prescriber or patient is appropriate; the queue preserves the coverage trail while the clinical team handles the clinical decision. Keeping those functions separate protects both the patient and the record.

Define ownership and handoffs

Prior authorization is cross-functional, so “the authorization team owns it” is usually incomplete. Assign roles by action. A technician may open the record and obtain plan instructions; a billing specialist may validate transaction details; a pharmacist may review a clinical-risk flag and patient communication; an owner or manager may remove staffing barriers and review aging; the prescriber supplies clinical information and makes treatment decisions. The person who creates the case should not be the only person who can close it.

Use a daily huddle for the oldest cases, the cases with a timing flag, and those awaiting an external response beyond the pharmacy’s expected follow-up interval. The purpose is not to recite every open item. It is to identify cases that lack a next action or a real owner. A second reviewer can catch a handoff that appears complete in a portal but was not communicated to the patient or reconciled to dispensing.

Measure delay without gaming the metric

Track a few operational measures: new cases, cases resolved, median age of open cases, number with no next action, number awaiting prescriber information, number requiring pharmacist review, and time from plan response to documented patient update. Segment them by plan type only if the data are reliable and privacy safeguards are in place. Do not reward a team for closing a case merely because it was transferred elsewhere. A closed case should show an actual disposition: paid, alternative selected by the authorized prescriber, patient decision documented, pending with a named external party and follow-up date, or another defined outcome.

Review exceptions, not just averages. A low median can coexist with a small group of very old cases. Read several records each month for evidence quality: does the note identify the plan instruction, the person contacted, and the next step? If not, redesign the template or training rather than blaming staff for a system that cannot express the work. For a related claim-level documentation framework, see Dispense Times’ below-cost reimbursement guide.

Keep Medicare rules in their proper lane

Federal requirements are important context, but they do not create a universal drug-authorization workflow. CMS’s Interoperability and Prior Authorization final rule applies to specified impacted payers and generally begins operational provisions in 2026. It requires decision timeframes of 72 hours for expedited and seven calendar days for standard requests for impacted payers other than QHP issuers on the Federally Facilitated Exchanges. CMS expressly states that the rule’s prior-authorization provisions do not apply to drugs. The related API requirements generally begin in 2027 and also exclude drug authorizations. A community pharmacy should not tell a patient that these timeframes govern a commercial or Part D drug request unless the governing plan materials say so.

For Medicare Part D, CMS describes a coverage determination as including a decision about whether an enrollee has met a prior-authorization or other utilization-management requirement. That is helpful vocabulary for a Part D workflow; it is not a substitute for the plan’s notice, formulary, or appeal instructions. Keep the actual Part D plan information with the case and distinguish it from a medical-benefit authorization.

Program-specific exceptions also belong in a separate lane. CMS says its 2026 Medicare GLP-1 Bridge uses a central processor for prior authorization, claims adjudication, and payment and operates outside the Part D coverage and payment flow. If a pharmacy serves affected patients, it should use the program’s materials and training—not apply that process to ordinary Part D or commercial claims. CMS also identifies 2026 interoperability and drug-prior-authorization rulemaking as proposed; proposed rules are a watchlist item, not a present operational mandate.

Before-you-open implementation checklist

1. Write a one-page case definition and exclusions for non-PA rejects.
2. Configure required fields: plan response, therapy/timing flag, owner, next action, and follow-up date.
3. Agree on pharmacist-review triggers and after-hours escalation policy.
4. Map prescriber-office contacts and approved communication channels.
5. Train staff to copy the plan’s stated request rather than paraphrasing it from memory.
6. Create a daily aging report and a weekly sample review.
7. Test the process with a simulated routine case and a potential therapy-interruption case.
8. Review privacy access, documentation retention, and any applicable state requirements with counsel or compliance leadership.

Frequently asked questions

Should every rejected prescription enter the prior-authorization queue?

No. Use a defined case definition. Eligibility, refill-too-soon, inventory, and coordination-of-benefits problems may need different workflows. The point is to create a reliable path for real authorization barriers, not a larger miscellaneous inbox.

Can pharmacy staff tell a patient when a plan will decide?

They can describe a verified plan instruction or program timeline, with its scope, and state when the pharmacy will follow up. They should not promise an outcome or apply a Medicare rule to an unrelated benefit.

What is the most important queue field?

The next action with an owner and date. A case may contain excellent history and still be unsafe if nobody knows what happens next.

Conclusion

A safer prior-authorization workflow is deliberately unglamorous: a reliable intake record, a small number of lanes, defined handoffs, visible aging, and patient communication that says what is known rather than what everyone hopes will happen. For an independent pharmacy, that discipline turns a recurring source of disruption into a controlled, reviewable process—and gives pharmacists more timely visibility when a coverage barrier may become a care barrier.

References

1. Centers for Medicare & Medicaid Services. CMS Interoperability and Prior Authorization Final Rule CMS-0057-F. January 17, 2024. Accessed July 19, 2026. CMS.
2. Centers for Medicare & Medicaid Services. Coverage Determinations. Accessed July 19, 2026. CMS.
3. Centers for Medicare & Medicaid Services. Electronic Prior Authorization Overview. Accessed July 19, 2026. CMS.
4. Centers for Medicare & Medicaid Services. 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F). April 5, 2023. Accessed July 19, 2026. CMS.
5. Centers for Medicare & Medicaid Services. Information for Pharmacies—Medicare GLP-1 Bridge. Accessed July 19, 2026. CMS.